Effects of MCI-154, a novel cardiotonic agent, on mean circulatory filling pressure in anesthetized dogs

Biological Evaluation of Polyherbal Ayurvedic Cardiotonic Preparation "Mahamrutyunjaya rasa"

Mahamrutyunjaya rasa (MHR), an Ayurvedic formulation, used as cardiotonic, contains potentially toxic compounds like aconitine, which are detoxified during preparation using traditional methods. Comparative toxicological evaluation of laboratory prepared formulation (F1) and two marketed formulations (F2 and F3) were performed based on their effects on viability of H9c2 cells and after single oral dose administration in mice. Cardioprotective effect of formulations at 25 and 50 mg/kg doses were studied in isoproterenol- (ISO-) induced myocardial infarcted rats. F1 and F2 did not affect the cell viability, while F3 decreased the cell viability in concentration and time-dependent manner. Rats administered with ISO showed significant increase in the serum levels of glutamate oxaloacetate transaminase, alkaline phosphotase, creatinine kinase isoenzymes, lactate dehydrogenase, and uric acid, while F1 and F2 treatment showed significant reduction in the same. F3 showed further increase in the serum levels of enzymes and uric acid in ISO-challenged rats. High pressure liquid chromatographic analysis of formulations showed higher concentration of aconitine in F3. Study shows that F1 and F2 possess cardioprotective property with higher safety, while formulation F3 cannot be used as cardioprotective due to its cytotoxic effects. Thus, proper quality assessment methods are required during preparation of traditional formulations.

MCI-154-induced relaxation in vascular smooth muscles of guinea pig

We investigated the vasorelaxant effects of MCI-154, a cardiotonic agent designed to target thin filaments in cardiac muscles in intact and skinned vessels from guinea pigs. In normal Krebs-Henseleit solution, MCI-154 (10(-7)-10(-4) M) inhibited the contractions induced by angiotensin II, (Ang II), endothelin-1 (ET-1), phenylephrine, and phorbol 12-myristate 13-acetate (PMA) in a concentration-dependent manner in guinea pig aorta. In Ca(2+)-free solutions, ET-1 and PMA caused slowly developing and sustained contractions in guinea pig aorta, whereas phenylephrine and caffeine induced transient contractions due to Ca2+ release from the sarcoplasmic reticulum (SR). MCI-154 (10(-7)-10(-4) M) inhibited the contractile responses to ET-1 and PMA. MCI-154 also reduced the contraction induced by Ca2+ release from phenylehrine- and caffeine-sensitive Ca2+ store sites. On the other hand, the relaxation response to MCI-154 was not affected by the presence of methylene blue, a guanylate cyclase inhibitor or by the removal of endothelial cells. MCI-154 decreased the Ca(2+)-activated tension development in saponin-treated skinned fibers from guinea pig femoral arteries. The effects of MCI-154 were not potentiated in the presence of protein kinase A (PKA), whereas those of cyclic AMP were potentiated, possibly because of lack of protein kinase A. The present experiments demonstrate that MCI-154 inhibits vascular contraction when the contractions are produced by any of three mechanisms: protein kinase C (PKC) activation, Ca2+ mobilization from store sites, or sensitization of contractile elements by Ca2+.

Electrophysiological comparison of the effects of MCI-154 on smooth muscles between mesenteric artery and vein of dogs

1. Effects of MCI-154, a cardiotonic vasodilator, on smooth muscles were compared in isolated mesenteric artery and vein of dog. 2. MCI-154 depolarized the membrane, and inhibited Ca(2+)- and K(+)-contractions more in the vein than in the artery. 3. Nerve-mediated and noradrenaline-induced contractions, and the excitatory junction potential (e.j.p.) were inhibited by MCI-154 in the vein and potentiated in the artery. 4. Compound action potentials of perivascular nerves and action potentials generated on the e.j.p. were not altered by MCI-154. 5. MCI-154 predominantly dilates venous muscles, and as a result would reduce cardiac outflow and lower systemic blood pressure.

Inhibitory actions of MCI-154 on guinea-pig femoral artery and vein preparations

In guinea-pig femoral artery and vein preparations, the effects of MCI-154 were investigated on: (1) membrane depolarizations produced by 29.6 mM [K+]0 (high-K) solution and noradrenaline (NA) and on e.j.p.s produced by perivascular nerve stimulation; (2) contractions produced by NA, high-K and perivascular nerve stimulation; and, (3) endothelium-dependent relaxation produced by acetylcholine (ACh). In both femoral artery and vein preparations, MCI-154 (up to 10(-5) M) did not change the resting membrane potential or the depolarization produced by high-K. In preparations of femoral vein but not femoral artery, MCI-154 reduced NA-induced depolarization. The contractions produced by NA and high-K were reduced by MCI-154, the former more than the latter. The actions of MCI-154 were more pronounced in the vein than in the artery. The excitatory junction potential and contractions produced by perivascular nerve stimulation in guinea-pig saphenous artery preparations were inhibited by MCI-154 (greater than 10(-7) M). ACh-induced relaxations of guinea-pig femoral artery preparations precontracted with high-K were not affected by MCI-154. It was concluded that MCI-154 is an antagonist at postjunctional alpha 2-adrenoceptors, and, at high concentrations, inhibits voltage-dependent Ca2+ influx in vascular smooth muscle cells. These actions may contribute to the hypotensive effect of this drug.

Improvement of postischemic contractile dysfunction of dog heart by MCI-154, a novel cardiotonic agent

The effects of MCI-154, a cardiotonic agent which has direct effects on cardiac myofilaments, on postischemic contractile dysfunction were studied in dog heart subjected to a 30-min occlusion of the left anterior descending coronary artery followed by reperfusion, and compared with the effects of milrinone and dobutamine, that have largely cyclic AMP-dependent mechanisms of action. Regional myocardial contractility (segment shortening) and tissue ATP levels were severely depressed in reperfused myocardium. MCI-154 (0.3 and 1 microgram/kg per min) improved the regional function of postischemic myocardium and decreased left ventricular end-diastolic pressure and systemic aortic pressure when infused i.v. from 30 min after reperfusion. The improvement of regional function caused by MCI-154 (1 microgram/kg per min) was more pronounced than that caused by milrinone (1 microgram/kg per min) or dobutamine (1 microgram/kg per min), although the drugs produced an equal increase in cardiac performance (peak positive left ventricular dP/dt). These results suggest that MCI-154 produces a more pronounced improvement of regional myocardial function than milrinone and dobutamine, presumably by increasing the responses of the contractile protein system to Ca2+. In this respect, MCI-154 would be of much benefit for the treatment of postischemic left ventricular dysfunction.